A detailed history of Mengis Capital Management, Inc. transactions in Viatris Inc stock. As of the latest transaction made, Mengis Capital Management, Inc. holds 36,672 shares of VTRS stock, worth $423,561. This represents 0.08% of its overall portfolio holdings.

Number of Shares
36,672
Previous 38,496 4.74%
Holding current value
$423,561
Previous $409,000 4.89%
% of portfolio
0.08%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$10.05 - $12.02 $18,331 - $21,924
-1,824 Reduced 4.74%
36,672 $389,000
Q1 2024

May 14, 2024

BUY
$11.27 - $13.53 $17,423 - $20,917
1,546 Added 4.18%
38,496 $459,000
Q4 2023

Feb 01, 2024

SELL
$8.77 - $10.85 $3,665 - $4,535
-418 Reduced 1.12%
36,950 $400,000
Q2 2023

Aug 08, 2023

SELL
$9.02 - $10.29 $10,363 - $11,823
-1,149 Reduced 2.98%
37,368 $372,000
Q1 2023

May 05, 2023

SELL
$9.2 - $12.26 $29,375 - $39,146
-3,193 Reduced 7.66%
38,517 $370,000
Q4 2022

Feb 01, 2023

SELL
$8.72 - $11.56 $373,782 - $495,519
-42,865 Reduced 50.68%
41,710 $464,000
Q3 2022

Nov 04, 2022

SELL
$8.48 - $11.13 $136,570 - $179,248
-16,105 Reduced 16.0%
84,575 $720,000
Q2 2022

Jul 19, 2022

SELL
$9.95 - $12.27 $62,426 - $76,981
-6,274 Reduced 5.87%
100,680 $1.05 Million
Q1 2022

May 02, 2022

SELL
$9.81 - $15.4 $41,506 - $65,157
-4,231 Reduced 3.81%
106,954 $1.16 Million
Q4 2021

Feb 04, 2022

BUY
$12.09 - $14.68 $16,333 - $19,832
1,351 Added 1.23%
111,185 $1.5 Million
Q3 2021

Nov 03, 2021

BUY
$13.25 - $15.13 $128,114 - $146,291
9,669 Added 9.65%
109,834 $1.49 Million
Q2 2021

Aug 16, 2021

BUY
$12.97 - $16.15 $408,152 - $508,224
31,469 Added 45.81%
100,165 $1.43 Million
Q1 2021

May 07, 2021

BUY
$13.59 - $18.54 $933,578 - $1.27 Million
68,696 New
68,696 $959,000

Others Institutions Holding VTRS

About Viatris Inc


  • Ticker VTRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,212,669,952
  • Market Cap $14B
  • Description
  • Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...
More about VTRS
Track This Portfolio

Track Mengis Capital Management, Inc. Portfolio

Follow Mengis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mengis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mengis Capital Management, Inc. with notifications on news.